Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Replimune Group, Inc. alleging securities fraud. The complaint claims the company made false statements about its business operations and failed to disclose FDA study design concerns and deficiencies in its BLA submission. The lawsuit covers investors who purchased Replimune securities between October 20, 2025 and April 10, 2026.